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A B S T R A C T
Purpose
This population-level study was conducted to define the health-related quality of life (HRQL) of
individuals living with and beyond colorectal cancer (CRC) and to identify factors associated with
poor health outcomes.
Patients and Methods
All individuals diagnosed with CRC in England in 2010 and 2011 who were alive 12 to 36 months
after diagnosis were sent a questionnaire. This included questions related to treatment, disease
status, other long-term conditions (LTCs), generic HRQL (EuroQol-5D), and cancer-specific
outcomes (Functional Assessment of Cancer Therapy and Social Difficulties Inventory items).
Results
The response rate was 63.3% (21,802 of 34,467 patients). One or more generic health problems
were reported by 65% of respondents, with 10% of patients reporting problems in all five
domains. The reporting of problems was higher than in the general population and was most
marked in those age less than 55 years. Certain subgroups reported a higher number of problems,
notably those with one or more other LTCs, those with active or recurrent disease, those with a
stoma, and those at the extremes of the age range ( 55 and 85 years). Of respondents without
a stoma, 16.3% reported no bowel control. Reversal of a stoma resulted in fewer severe bowel
problems but more moderate problems than those who had never had a stoma. A quarter of rectal
cancer respondents (25.1%) reported difficulties with sexual matters (compared with 11.2% of
colon cancer respondents).
Conclusion
This study demonstrates the success of a national patient-reported outcomes survey. The results
have the potential to support system-wide improvement in health outcomes through the
identification of particular challenges faced by individuals after treatment for CRC.
J Clin Oncol 33:616-624. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The population living with or beyond a diagnosis of
colorectal cancer (CRC) is increasing and is pro-
jected to increase from 1.2 million in 2012 to 1.5
million in 2022 in the United States1 and from
240,000 in 2010 to 630,000 by 2040 in the United
Kingdom.2 Survivors of cancer report significant
unmet needs.3,4 Targeted aftercare may improve
care quality through focused delivery of resources.
However, this requires evidence of the prevalence,
extent, and impact of resultant morbidities.
Patient-reported outcomemeasures (PROMs)
may be used to drive changes in the organization
and delivery of health care.5 Provider organizations
are increasingly collecting cancer PROMs, but these
data are not yet available on a national basis. This is
in contrast topatient-reportedexperiencemeasures,
such as the English National Cancer Patient Experi-
ence Survey,6 which collects information on pa-
tients’ self-reported health care experience rather
than self-reported outcomes (as measured by
PROMs). Complementary information on survival
is collected by theNational Cancer Registration Ser-
vice (NCRS).7Theadditionofpatient-reportedout-
comes to robust survival and experience data will
provide the potential for a comprehensive quality
account of cancer services.
A growing body of evidence highlights the un-
wanted consequences of CRC treatment, including
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bowel, urinary, and sexual problems.8-10Most of this information has
been derived from highly selected groups, including clinical trials
or small-scale retrospective hospital series, with a lack of whole
population-based data. Although studies increasingly use cancer
registries to identify more representative samples,11 to our knowl-
edge, none have previously reported at a national level in the
United Kingdom.
Our primary objective was to define, at a population level,
the health-related quality of life (HRQL) of individuals living
with and beyond CRC diagnosed 12 to 36 months earlier in
England. The secondary objective was to identify factors associated
with poor reported health outcomes that could be used to support
enhanced aftercare.
PATIENTS AND METHODS
Study Design and Survey Process
The studydesign followed that of a recentpilot study.12 Individuals older
than age 16 years surviving 12 to 36 months after a diagnosis of CRC (Inter-
national Statistical Classification of Disease and Related Health Problems,
Tenth Revision13 codes C18 to C20) in 2010 or 2011 and treated in the
NationalHealth Service inEnglandwere identified via theNCRS.Weestimate
that more than 98% of all eligible individuals were identified.14 Results from
the pilot study demonstrated that HRQL and physical problems remained
relatively constant with time (between 12 and 60 months after diagnosis)12;
hence, only patients who were 12 to 36months after diagnosis were included.
Individuals were sent a questionnaire accompanied by a letter from their
treating cancer center. Patients consented by returning completed question-
naires and declined by not returning the questionnaires or returning blank
questionnaires. Two reminders were sent to nonresponders. A dedicated free-
phone helpline was provided to resolve any queries.
Permission to approachpatientswithout informed consentwas givenby
theNational InformationGovernance Board [ref ECC5-02(FT8)/12]. Ethical
approval for research on the data captured by the survey was granted by the
East of Scotland Research Ethics Committee (ref 08/S0501/66).
Questionnaire Design
The specific components of the questionnaire and the cognitive testing
performedhavebeendescribedelsewhere.12Briefly, the content (DataSupple-
ment) included questions related to treatment, disease status, long-term con-
ditions (LTCs), generic HRQL (EuroQol-5D [EQ-5D]),15 CRC-specific
outcomes (FunctionalAssessment ofCancerTherapy [FACT]),16 social prob-
lems (Social Difficulties Inventory),17 and experience of care.6 Respondents
could provide free text comments (to be reported elsewhere).
Data Handling
Age, sex, tumor site, and Dukes’ stage of disease at diagnosis were ob-
tained from cancer registration data. Agewas categorized as less than 55, 55 to
64, 65 to 74, 75 to 84, and 85 years. Deprivation category was based on the
Index ofMultiple Deprivation,18 derived using the postcode of residence.
A number of variables were derived from the questionnaire data. Self-
reported racewas grouped intowhite andnonwhite. Participantswere asked if
they had any other LTCs at the time of questionnaire completion and to
identify these from a given list (Data Supplement). This variable was catego-
rized as none, one, two, or three other LTCs. Information on self-reported
disease status (remission, treatedbut still present,no treatment, recurrence,ornot
certain), treatments (surgery, radiotherapy, andchemotherapy), and stomastatus
(present, reversed, or never formed) was taken from the questionnaire. Records
withmissing datawere retained and categorized as not reported.
The five-level version of the EQ-5D15 records problems on five domains
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
These data may be summarized as a single index score using a standard
crosswalk algorithm19; scores range from0.5 to 1, where 1 is the maximum
score for an individual reportingnoproblems in anydomain.Thedistribution
of the EQ-5D scores is left skewed (median, 0.84; interquartile range, 0.71 to 1.0),
with a large peak at the right tail (those scoring 1), and this makes it difficult to
model. A simple approach was used to count the number of domains with a
problem reported, regardless of the severity of the problem. Records with no
response onone ormore domainswere excluded from this analysis (4.6%).
Cancer-specific questions from FACTwere examined separately (FACT
total score could not be calculated because not all questionswere included as a
result of previous cognitive testing).4 Outcomes relating to bowel control,
diarrhea, and urinary function are presented here. Analysis of questions relat-
ing to bowel function was limited to patients without a stoma, because it was
Identified by NCRS
(n = 35,213)
Eligible for
participation in survey
(n = 34,467)
Completed questionnaires
returned*
(n = 21,802)
Free-text comments
provided
(n = 5,634)
Calls to helpline
  Opted out/too ill
  General inquiry
  Reported patient death
  Annoyed about survey
  Other reason
(n = 1,129)
(n = 458)
(n = 308)
(n = 104)
(n = 28)
(n = 231)Nonresponse
  Undelivered
  Opted out
  Nothing returned
(n = 12,665)
(n = 241)
(n = 4,956)
(n = 7,468)
Died before/during
survey process
(n = 746)
Fig 1. Flowchart showing survey pro-
cess and responses. Response rate for
survey was 63.3% based on number of
questionnaires returned (n  21,802) di-
vided by number of patients eligible for
participation (n  34,467). (*) All question-
naires were included, whether partially or
fully completed. Information about the
completeness of the questions/sections
used in this study is available in Appendix
Table A2 (online only). NCRS, National
Cancer Registration Service.
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felt that individuals with a stoma present could interpret the questions in
different ways. Records with no response to the question of interest were
excluded (range, 4.4% to 8.5%).
The Health Survey for England 2011 (HSE 2011)20 provided com-
parison with the general population. This household survey (8,610
individuals age  16 years) measured HRQL using the EQ-5D. The
CRC PROMs and HSE data sets were age and sex matched, creating a
comparable sample of 4,615 individuals with EQ-5D responses on all
five domains (this lower number reflects the different age profiles of the
two surveys).
Table 1. Demographics and Clinical Characteristics of the Respondents by Tumor Site
Demographic or
Characteristic
Colon Rectosigmoid Rectum
P
Overall
No. of
Respondents %
No. of
Respondents %
No. of
Respondents %
No. of
Respondents %
Age, years  .001
 55 1,054 7.8 167 11.0 819 12.2 2,040 9.4
55-64 2,938 21.6 385 25.5 1,831 27.3 5,154 23.6
65-74 4,869 35.9 558 36.9 2,397 35.7 7,824 35.9
75-84 3,876 28.5 342 22.6 1,415 21.1 5,633 25.8
 85 840 6.2 60 4.0 251 3.7 1,151 5.3
Sex  .001
Male 7346 54.1 952 63.0 4,385 65.3 12,683 58.2
Female 6,231 45.9 560 37.0 2,328 34.7 9,119 41.8
Index of Multiple Deprivation .002
1, least deprived 3,501 25.8 343 22.7 1,640 24.4 5,484 25.2
2 3,399 25.0 363 24.0 1,598 23.8 5,360 24.6
3 2,932 21.6 326 21.6 1,484 22.1 4,742 21.8
4 2,212 16.3 271 17.9 1,175 17.5 3,658 16.8
5, most deprived 1,533 11.3 209 13.8 816 12.2 2,558 11.7
Race .346
White 12,905 95.1 1,435 94.9 6,418 95.6 20,758 95.2
Nonwhite 299 2.2 30 2.0 125 1.9 454 2.1
Not known 373 2.7 47 3.1 170 2.5 590 2.7
No. of long-term conditions  .001
None 2,750 20.3 319 21.1 1,582 23.6 4,651 21.3
1 3,901 28.7 484 32.0 2,091 31.1 6,476 29.7
2 2,872 21.2 315 20.8 1,336 19.9 4,523 20.7
 3 3,371 24.8 307 20.3 1,303 19.4 4,981 22.8
Not reported 683 5.0 87 5.8 401 6.0 1,171 5.4
Dukes’ stage of disease at diagnosis  .001
A 1,818 13.4 244 16.1 1,471 21.9 3,533 16.2
B 5,412 39.9 431 28.5 1,533 22.8 7,376 33.8
C 4,554 33.5 588 38.9 2,496 37.2 7,638 35.0
D 862 6.3 107 7.1 410 6.1 1,379 6.3
Not known 931 6.9 142 9.4 803 12.0 1,876 8.6
Disease status  .001
Remission 10,442 76.9 1,158 76.6 5,042 75.1 16,642 76.3
Treated but cancer still present 551 4.1 98 6.5 422 6.3 1,071 4.9
No treatment 154 1.1 16 1.1 34 0.5 204 0.9
Recurrence 365 2.7 32 2.1 175 2.6 572 2.6
Not certain 1,207 8.9 130 8.6 724 10.8 2,061 9.5
Not reported 858 6.3 78 5.2 316 4.7 1,252 5.7
Treatment  .001
Surgery alone 7,446 54.8 650 43.0 1,992 29.7 10,088 46.3
Surgery  chemotherapy 4,832 35.6 523 34.6 880 13.1 6,235 28.6
Surgery  chemotherapy  radiotherapy 326 2.4 181 12.0 2,437 36.3 2,944 13.5
Surgery  radiotherapy 91 0.7 46 3.0 696 10.4 833 3.8
Other 561 4.1 77 5.1 590 8.8 1,228 5.6
Not reported 321 2.4 35 2.3 118 1.8 474 2.2
Stoma status  .001
No stoma 9,655 71.1 739 48.9 1,427 21.3 11,821 54.2
Reversed 957 7.0 350 23.1 2,071 30.9 3,378 15.5
Present 1,327 9.8 312 20.6 2,848 42.4 4,487 20.6
Not reported 1,638 12.1 111 7.3 367 5.5 2,116 9.7
Total 13,577 100 1,512 100 6,713 100 21,802 100
Chemotherapy plus radiotherapy, chemotherapy alone, or radiotherapy alone.
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Statistical Analysis
Descriptive statistics were used to compare respondent characteristics,
EQ-5D domain responses, and cancer-specific outcomes across CRC sites
(colon, rectosigmoid junction, and rectum). 2 tests were used to compare
categorical variables. Multivariable logistic regression was performed using a
binaryoutcomevariable—perfecthealth (noproblemsonEQ-5D)or less than
perfect health (oneproblem).Variables predictive of less thanperfect health
were chosen initially based on their a priori clinical and public health impor-
tance, and final model selection was informed by univariable results and
statistical validity (eg, collinearity among variables). Analyses were performed
using Stata version 13 (Stata, College Station, TX).
RESULTS
Response Rates
NCRS identified35,213 individuals diagnosedwithCRC12 to36
months previously; 746 of individuals (2.1%) died before or during
the survey process, giving a final eligible sample of 34,467 (Fig 1). Of
these, 21,802 individuals returned completedquestionnaires, generat-
ing a 63.3% response rate (RR). Respondent and nonrespondent
characteristics were compared (Appendix Table A1, online only).
Individuals age less than 55 years (RR, 56.0%) or more than 85 years
(RR, 49.0%), those from a nonwhite ethnic group (Asian RR, 42.0%;
black RR, 43.1%), and those living in the most socioeconomically
deprived areas (RR, 52.1%) were less likely to participate.
Data Quality
Missingdata levelswere low,at approximately5%formostfields.
For example, 5.4% of respondents did not answer the question on
LTCsand5.7%didnot report theirdisease status (AppendixTableA2,
online only).
Characteristics of the Population
Across the sample, 62.3% of patients were diagnosed with colon
cancers, 30.8% with rectal cancers, and 6.9% with rectosigmoid tu-
mors. Rectal cancer respondents were younger, with a higher propor-
tion being male (Table 1). Other LTCs were common, with only one
fifth (21.3%) of patients reporting no LTCs and 43.5% of patients
reporting two or more. Overall, 6.7% of respondents were diagnosed
with metastatic disease (Dukes’ stage D), and three quarters (76.3%)
of respondents reported being in remission. Of the respondents,
92.3% reported having surgery, 46.8% chemotherapy, and 19.7%
radiotherapy. The figures for surgery and chemotherapy were similar
across the three sites, whereas, as would be anticipated as a result of
best practice, a higher proportion of the group with rectal cancer
(54.3%) received radiotherapy (compared with 3.5% of respondents
with colon cancer and 16.9% of respondents with rectosigmoid can-
cer). A stoma was present in 9.8% of respondents with colon cancer,
20.6%of respondentswith rectosigmoidcancer, and42.4%of respon-
dents with rectal cancer. In total, 34.9% of patients reported having
had a stoma reversed.
Generic PROMs
A third of all respondents (34.5%) reported perfect health (no
problems on any of the EQ-5D domains). Respondents with rectal
cancerweremore likely to report problems (70.9%) than respondents
with rectosigmoid or colon cancer (63.8% and 63%, respectively;
P  .001; Table 2). Problems were most commonly reported with
pain/discomfort (43.1%) and usual activities (42.9%). Respondents
with rectal cancer were significantlymore likely to report problems in
all domains except the mobility domain. Table 3 lists the number of
problems reported in relation to the different population characteris-
tics. Reporting of  one problem was highest in those with active
(90.8%) or recurrent (87.9%) disease, those with three other LTCs
(83.3%), thosewith a stomapresent (80.3%), and thoseolder thanage
85 (79.4%).Overall, 9.6%of respondents indicated having some level
ofprobleminallfivedomains, and thiswashighest in thosewithactive
disease (24.1%) and those with three other LTCs (20.6%).
These effects persisted in multivariable analysis where  three
LTCs (odds ratio [OR], 5.56; 95%CI, 5.00 to 6.18 compared with no
LTCs), active disease (OR, 5.38; 95% CI, 4.30 to 6.73 compared with
remission), and presence of a stoma (OR, 2.34; 95% CI, 2.12 to 2.59
compared with no stoma) were the strongest predictors of less than
perfect health (problems on  one domain). In addition, being fe-
male, living in a more deprived area, and receiving treatment includ-
ing radiotherapy and/or chemotherapy were predictive of less than
perfect health. Individuals age 55 to 84 years were less likely to report
problems (compared with those 55 years old), whereas the oldest
age group ( 85 years) reported similar outcomes to those age less
than 55 years.
Survivors of CRCweremore likely to report problems on one
domain than the general population (68.8% v 59.9% in the matched
HSE 201120 data; P .001). This was mainly seen in those younger
than age 55 years, where 73.1% of survivors of CRC and 49.6% of the
general population reported problems (P  .001; Fig 2). Outcomes
were similar in the older age groups. Survivors of CRC with no other
LTCs reportedworsehealth than thegeneralpopulationwithnoLTCs
(58.7% v 40.2% reporting problems, respectively; P .001).
Table 2. EuroQol-5D Domain Responses by Tumor Site
Domain
% of Patients
P
% of All
Patients
(N  20,794)
Colon
(n  12,920)
Rectosigmoid
(n  1,461)
Rectum
(n  6,413)
Mobility .077
No problems 63.6 64.3 62.1 63.2
Problems 36.4 35.7 37.9 36.8
Total 100 100 100 100
Self-care .001
No problems 83.6 83.3 81.7 83.0
Problems 16.4 16.7 18.3 17.0
Total 100 100 100 100
Usual activities  .001
No problems 59.9 58.9 51.1 57.1
Problems 40.1 41.1 48.9 42.9
Total 100 100 100 100
Pain/discomfort  .001
No problems 60.5 58.5 49.1 56.9
Problems 39.5 41.5 50.9 43.1
Total 100 100 100 100
Anxiety/
depression  .001
No problems 65.4 63.7 60.3 63.7
Problems 34.6 36.3 39.7 36.3
Total 100 100 100 100
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Table 3. Number of Generic Health Problems Reported (using the EuroQol-5D domains) by Patient Demographic or Clinical Characteristic
Demographic or Characteristic
No. of
Respondents
No. of Domains With Problems
Reported (% of respondents)
Odds of Reporting
 One Problem
None 1 2 3 4 5 Odds Ratio 95% CI P
Age, years  .001
 55 1,999 27.6 20.1 17.9 13.4 11.0 10.2 1.00
55-64 4,998 36.1 20.1 14.0 11.2 9.5 9.1 0.62 0.55 to 0.70
65-74 7,497 40.0 18.7 12.2 10.8 9.6 8.7 0.46 0.41 to 0.52
75-84 5,262 30.5 16.7 14.6 15.0 13.5 9.7 0.63 0.56 to 0.72
 85 1,038 20.6 13.3 14.6 16.9 18.6 16.0 1.03 0.84 to 1.26
Sex  .001
Male 12,201 36.5 17.6 13.6 12.0 10.6 9.6 1.00
Female 8,593 31.7 19.5 14.3 13.2 11.9 9.4 1.34 1.26 to 1.43
Index of Multiple Deprivation  .001
1, least deprived 5,281 38.7 19.9 14.7 10.8 9.5 6.3 1.00
2 5,142 36.4 20.1 13.5 13.0 9.7 7.3 1.07 0.99 to 1.17
3 4,512 33.4 18.5 14.2 12.5 11.6 9.9 1.17 1.07 to 1.28
4 3,454 31.5 16.4 13.1 13.3 13.4 12.3 1.18 1.07 to 1.30
5, most deprived 2,405 27.7 14.3 13.4 13.8 14.0 16.8 1.32 1.17 to 1.48
Race .387
White 19,869 34.6 18.6 13.9 12.5 11.1 9.3 1.00
Nonwhite 431 31.6 13.0 14.2 14.4 12.8 14.2 0.98 0.78 to 1.22
Not known 494 31.4 16.2 13.8 12.1 11.5 15.0 1.16 0.94 to 1.42
No. of long-term conditions  .001
None 4,523 47.6 21.4 14.0 7.8 5.5 3.6 1.00
1 6,253 40.2 20.6 14.3 11.0 8.2 5.7 1.51 1.39 to 1.64
2 4,316 31.4 18.6 14.6 13.7 12.0 9.7 2.40 2.18 to 2.64
 3 4,666 16.7 12.1 12.5 17.9 20.3 20.6 5.57 5.01 to 6.19
No response 1,036 36.1 19.7 14.4 12.6 8.9 8.3 1.53 1.32 to 1.78
Dukes’ stage of disease at diagnosis  .001
A 3,373 40.8 19.7 12.9 10.9 9.1 6.7 1.00
B 6,999 37.9 18.8 13.5 11.3 9.8 8.7 1.09 0.99 to 1.20
C 7,312 31.3 18.4 14.8 13.4 12.2 9.9 1.24 1.11 to 1.37
D 1,328 22.4 17.0 13.9 16.7 15.7 14.2 1.36 1.15 to 1.62
Not known 1,782 31.0 15.9 13.6 13.3 12.9 13.3 1.16 1.01 to 1.33
Disease status  .001
Remission 16,082 39.8 19.6 13.6 11.4 9.1 6.5 1.00
Treated but still present 1,028 9.2 12.6 14.9 17.3 21.8 24.1 5.11 4.07 to 6.42
No treatment 176 29.0 12.5 13.6 10.2 14.2 20.5 1.32 0.92 to 1.89
Recurrence 554 12.1 12.8 15.9 19.7 20.4 19.1 4.14 3.17 to 5.40
Not certain 1,951 14.3 14.4 15.5 16.7 18.9 20.1 3.28 2.86 to 3.76
No response 1,003 28.3 16.7 13.4 13.9 12.7 15.2 1.38 1.18 to 1.60
Treatment  .001
Surgery alone 9,591 39.7 18.2 12.7 11.5 10.2 7.8 1.00
Surgery  chemotherapy 6,043 34.4 20.6 14.7 12.0 10.0 8.4 1.31 1.20 to 1.43
Surgery  chemotherapy  radiotherapy 2,833 24.3 17.2 15.9 15.3 14.1 13.2 1.45 1.29 to 1.64
Surgery  radiotherapy 798 25.9 15.0 14.4 17.0 13.7 13.9 1.34 1.12 to 1.61
Other† 1,167 26.0 16.4 14.1 13.7 14.7 15.2 1.35 1.15 to 1.59
No response 362 23.8 13.0 14.1 12.2 17.7 19.3 1.45 1.10 to 1.91
Stoma status  .001
No stoma 11,372 39.8 19.0 12.8 11.3 9.9 7.3 1.00
Reversed 3,269 34.9 20.5 15.7 12.7 9.1 7.1 1.43 1.30 to 1.57
Present 4,309 19.7 15.8 15.7 15.8 15.9 17.1 2.34 2.12 to 2.59
No response 1,844 35.7 17.4 13.1 11.7 11.9 10.2 1.06 0.95 to 1.18
Site
Colon 12,920 37.0 18.5 13.3 11.7 10.7 8.8
Rectosigmoid 1,461 36.2 18.1 14.2 11.7 9.5 10.3
Rectum 6,413 29.1 18.3 15.0 14.2 12.5 11.0
Total 20,794 34.5 18.4 13.9 12.5 11.2 9.6
Adjusted for all variables in the table with the exception of tumor site as a result of the correlation with treatment and stoma status.
†Chemotherapy plus radiotherapy, chemotherapy alone, or radiotherapy alone.
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Cancer-Specific PROMs
Bowel control. Analysis of questions relating to bowel function
was limited to those without a stoma present. Overall, 16.3% of re-
spondents (without a stoma) reported having no control of their
bowels (Table 4). This was higher in the group with colon cancer
(17.5% compared with 15.4% and 13.0% of patients with rectosig-
moid and rectal cancer, respectively; P .001); however, the propor-
tion answering “a little” or “somewhat” (moderate problems) was
higher in the rectal cancer group (26.0% v 13.5% and 18.3% in the
colon and rectosigmoid groups, respectively; P .001). Patients with
a reversed stoma were less likely to report having no bowel control
than those who never had a stoma (12.0% v 16.6%, respectively; P
.001) but were more likely to report moderate problems (“a little” or
“somewhat”) than those with no stoma (25.9% v 14.0%, respectively;
P  .001). Overall, 6.7% of respondents reported having diarrhea
“quite a bit” or “very much,” and this was similar across the three
tumor sites (P .353).
Urinary function. The proportion of respondents reporting
problemswith difficulty urinating or leaking urinewas low; 3.8% and
4.6% of respondents answered “quite a bit” or “very much” to the
questions regardingdifficultyurinatingand leakingurine, respectively
(Table4).Ahigherproportionof respondents reportedproblemswith
urinatingmore frequently (12.7%).Whenconsidered together, 15.4%
of respondents answered “quite a bit” or “very much” to any of the
three urinary function questions. The figure was higher for the rectal
cancer group than the colon and rectosigmoid groups (17.9%, 14.1%,
and 15.1%, respectively; P .001). By sex, the figures were 16.0% in
males and 14.5% in females (P .004).
Body image and sexual matters. Overall, 10.1% of respondents
reported difficulties with their appearance or body image (answered
“quite abit”or “verymuch”), and thispercentagewashigher in the rectal
group (13.9% v 9.8% in the rectosigmoid group and 8.2% in the colon
group;P .001;Table4).Individualswithastoma(ofwhomthemajority
had rectal cancer) reportedmoredifficulties (20.9% v6.6%and10.1%in
the no stoma and reversed stoma groups, respectively;P .001).
Rectal cancer respondents were more likely to report difficulties
with sexual matters (25.1% answered “quite a bit” or “very much” v
11.2% of colon and 16.1% of rectosigmoid cancer respondents; P
.001; Table 4). Of those with a stoma present, 27.2% reported sexual
difficulties compared with 10.8% without a stoma (P .001). After
radiotherapy, 30.1% of respondents reported sexual difficulties com-
paredwith 12.4%whowere not irradiated (P .001). A high propor-
tion of respondents (36.9%) selected “does not apply” as their answer
to the sexual difficulties question.
DISCUSSION
To our knowledge, this is the first study to report theHRQL outcome
of a large nonselected national population living with and beyond a
diagnosis of CRC. The major finding that more than one third of
individuals surviving 12 to 36months fromadiagnosis of CRC report
being in perfect health (ie, no problems on EQ-5D) is reassuring.
However, certain subgroups report more problems, notably those
with one or more other LTCs, those with active or recurrent disease,
those with a stoma, and those at the extremes of the age range ( 55
and  85). The results confirm emergent findings from previous
smaller studies21-24 and identify groups thatmay have ongoing health
challenges requiring targeted support and services.
Poorer HRQL, relative to the general population, was most
marked in the younger age group, with little difference seen in those
older than age 65. This has been suggested previously by a single-
institution study of 309 survivors inGermany.21,22 This age effectmay
be explained by the gap hypothesis of quality of life,25 with younger
populationsexpectingtolive inrelativelygoodhealth,whileolderpatients
mayhave lower expectations or already be livingwith other LTCs.
Just more than 16% of all survivors of CRC without a stoma
reportedhavingno control of their bowels,with a further 17%report-
ingmoderate problems (little or some control). These problems were
not confined to the rectal cancer group and were highly prevalent
relative to the general population. In HSE 2011,20 9% of those older
than age 65 answered “yes” to the question, “Do you suffer from
problemswithcontrollingyourbowels?”Reversalof a stomaappeared
to result in fewer severebowel problemsbutmoremoderateproblems
than those who had never had a stoma. This finding requires further
investigation. Concerning sexual matters, 15.9% of respondents re-
ported experiencing severe difficulties (“quite a bit” or “very much”)
withpatientswithrectal cancer reportingahigherpercentage (25.1%).
Obtaining reliable intelligence on this subject is complex.26 In one
trial, baseline and 2-year sexual function questions were answered by
just 21% and 11% of women, respectively.10 In the current study,
although only 5.8%gave no response,more than one third of respon-
dents answered “does not apply,” and this response was higher in
women thanmen (48.3% and 28.9%, respectively). The difficulties in
capturing responses to questions on sexual function may explain the
wide variation in results fromprevious studies; estimates of incidence
of sexual dysfunction in survivors of CRC range from 23% to 69% in
men and 19% to 62% in women.27
Severeurinaryproblemswere reportedby15.4%of respondents.
This relatively low proportion is reassuring. Research in the United
States has shown that older survivors of CRC report similar levels of
urinary incontinence compared with those without cancer.28
This study highlights easily identifiable factors associated with
poor reported health outcomes. This emerging intelligence must be
used by national initiatives, such as the National Cancer Survivor
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Fig 2. Percentage of respondents reporting less than perfect health ( one
problem on the EuroQol-5D domains) in a matched sample of colorectal
patient-reported outcome measures (PROMs) and Health Survey for England
2011 data (n  4,615).
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Initiative in England,29 to generate risk-stratified pathways of after-
care. Coordination of care has been shown to be important in driving
up the quality of supportive care in CRC.4 Servicesmust ensure this is
provided to individuals at increased risk of morbidity. Similarly,
cost-effective interventions for the alleviation of bowel morbidity
after cancer have been identified. For example, a randomized trial
found that structured algorithm-driven management of patients
with GI symptoms after pelvic irradiation can give sustained
Table 4. Cancer-Specific Patient-Reported Outcomes by Tumor Site
Question
Colon Rectosigmoid Rectum
P
Overall
No. of Patients % No. of Patients % No. of Patients % No. of Patients %
I have control of my bowels (in the
past week)  .001
Very much 5,277 52.1 485 46.6 1,152 34.4 6,914 47.6
Quite a bit 1,718 17.0 206 19.8 896 26.7 2,820 19.4
Somewhat 902 8.9 128 12.3 552 16.5 1,582 10.9
A little 463 4.6 62 6.0 317 9.5 842 5.8
Not at all 1,771 17.5 160 15.4 436 13.0 2,367 16.3
Total 10,131 100 1,041 100 3,353 100 14,525 100
I have diarrhea (in the past week)  .001
Not at all 6,328 64.2 662 65.2 1,832 56.4 8,822 62.5
A little 2,247 22.8 245 24.1 893 27.5 3,385 24.0
Somewhat 621 6.3 51 5.0 299 9.2 971 6.9
Quite a bit 439 4.5 29 2.9 153 4.7 621 4.4
Very much 222 2.3 28 2.8 72 2.2 322 2.3
Total 9,857 100 1,015 100 3,249 100 14,121 100
I have difficulty urinating (in the past week)  .001
Not at all 10,439 84.1 1,125 81.8 4,670 75.8 16,234 81.4
A little 1,211 9.8 158 11.5 884 14.3 2,253 11.3
Somewhat 371 3.0 45 3.3 294 4.8 710 3.6
Quite a bit 185 1.5 27 2.0 165 2.7 377 1.9
Very much 204 1.6 21 1.5 149 2.4 374 1.9
Total 12,410 100 1,376 100 6,162 100 19,948 100
I urinate more frequently than usual (in the
past week)  .001
Not at all 6,524 52.1 738 52.9 2,940 47.1 10,202 50.6
A little 3,279 26.2 342 24.5 1,653 26.5 5,274 26.2
Somewhat 1,254 10.0 141 10.1 733 11.7 2,128 10.6
Quite a bit 1,005 8.0 116 8.3 591 9.5 1,712 8.5
Very much 461 3.7 57 4.1 323 5.2 841 4.2
Total 12,523 100 1,394 100 6,240 100 20,157 100
I leak urine (in the past week)  .001
Not at all 8,964 72.4 967 70.4 4,192 67.5 14,123 70.8
A little 2,501 20.2 295 21.5 1,379 22.2 4,175 20.9
Somewhat 417 3.4 57 4.2 266 4.3 740 3.7
Quite a bit 291 2.4 29 2.1 209 3.4 529 2.7
Very much 204 1.6 25 1.8 160 2.6 389 1.9
Total 12,377 100 1,373 100 6,206 100 19,956 100
Have you had any difficulty concerning
your appearance or body image?
(in the past month)  .001
No difficulty 8,019 62.2 854 59.3 3,412 53.0 12,285 59.1
A little 2,416 18.7 306 21.3 1,593 24.7 4,315 20.8
Quite a bit 615 4.8 65 4.5 509 7.9 1,189 5.7
Very much 441 3.4 76 5.3 388 6.0 905 4.4
Does not apply 1,411 10.9 138 9.6 537 8.3 2,086 10.0
Total 12,902 100 1,439 100 6,439 100 20,780 100
Have you had any difficulty concerning
sexual matters? (in the past month)  .001
No difficulty 5,301 41.6 564 39.2 1,941 30.6 7,806 38.0
A little 1,057 8.3 150 10.4 698 11.0 1,905 9.3
Quite a bit 580 4.5 94 6.5 546 8.6 1,220 5.9
Very much 854 6.7 137 9.5 1,045 16.5 2,036 9.9
Does not apply 4,958 38.9 493 34.3 2,121 33.4 7,572 36.9
Total 12,750 100 1,438 100 6,351 100 20,539 100
NOTE. Respondents stating that they had a stoma present and those who did not respond to the stoma question were excluded from this analysis.
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clinical improvement in bowel function.30 The magnitude of bowel
control problems reported in this study supports the widespread im-
plementation of such interventions.
The survey achieved a response rate of 63%. This is higher than
similar, but smaller, studies of survivors of CRC in the United States
(54% response)31 andCanada (34% response)32 and comparable to a
recent study of US veterans with CRC (63% response).4 Studies from
the Netherlands have reported higher response rates ( 70%), al-
though some screening for eligibility was undertaken (eg, excluding
terminally ill patients).23,33 Our response rate is reported according to
guidelines34 without exclusion or screening of eligible individuals.
There were differences in the characteristics of those who did and did
not respond, with the elderly, ethnicminorities, and those frommore
socioeconomically deprived areas being less likely to participate.
Given the characteristics of the nonrespondents, it is likely that they
wouldexperiencepooreroutcomes and that the results presentedhere
may underestimate the true impact of CRC.
The analysis of HRQL focused only on the reporting (or not) of
problemson theEQ-5Ddomains.Thedistributionof theEQ-5Ddata
makes any analysis complex. In addition, we would argue that the
calculation of scores from patient responses using weights from the
general population is flawed.Toovercome this, a simple approachhas
been presented.
Itemswere selected from the FACT subscales as a result of previ-
ous cognitive testing.4 The effect of omission of items on the psycho-
metric properties is not known. However, single-item responses have
beenevaluated separately, andanyeffect is likely tobe similar across all
subsample groups (ie, colon, rectosigmoid, rectal cancer).
Finally, this study relies on self-reports that have not been
verified through comparisonwith patient records or other sources.
Encouragingly, however, in a large study of patients with breast
cancer, excellent concordance was found in regard to disease- and
treatment-related information between the medical record and
patient self-report.35
This study demonstrates the success of a national patient-
reported outcomes survey. Although one third of respondents re-
ported no problems on assessment of HRQL, the results identify
subgroups that aremore likely to report problems. This approach has
the potential to support system-wide improvement through the iden-
tification of particular challenges faced by individuals after treatment
for CRC and those at greatest risk of poor outcomes.
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Appendix
Table A1. Comparison of Demographics and Clinical Characteristics Between Respondents and Nonrespondents
Demographic or Clinical
Characteristic
Nonrespondents Respondents
Total No. Response Rate (%)No. % No. %
Sex
Male 6,897 54.5 12,683 58.2 19,580 64.8
Female 5,768 45.5 9,119 41.8 14,887 61.3
Total 12,665 100.0 21,802 100.0 34,467 63.3
Age at diagnosis, years
 55 1,605 12.7 2,040 9.4 3,645 56.0
55-64 2,457 19.4 5,154 23.6 7,611 67.7
65-74 3,735 29.5 7,824 35.9 11,559 67.7
75-84 3,669 29.0 5,633 25.8 9,302 60.6
 85 1,199 9.5 1,151 5.3 2,350 49.0
Total 12,665 100.0 21,802 100.0 34,467 63.3
Index of Multiple Deprivation
1, least deprived 2,328 18.4 5,484 25.2 7,812 70.2
2 2,730 21.6 5,360 24.6 8,090 66.3
3 2,649 20.9 4,742 21.8 7,391 64.2
4 2,609 20.6 3,658 16.8 6,267 58.4
5, most deprived 2,349 18.5 2,558 11.7 4,907 52.1
Total 12,665 100.0 21,802 100.0 34,467 63.3
Race
White 8,702 68.7 16,079 73.8 24,781 64.9
Mixed 35 0.3 40 0.2 75 53.3
Asian 236 1.9 171 0.8 407 42.0
Black 189 1.5 143 0.7 332 43.1
Other 131 1.0 124 0.6 255 48.6
Not known 3,372 26.6 5,245 24.1 8,617 60.9
Total 12,665 100.0 21,802 100.0 34,467 63.3
Year of diagnosis
2010 5,968 47.1 10,523 48.3 16,491 63.8
2011 6,697 52.9 11,279 51.7 17,976 62.7
Total 12,665 100.0 21,802 100.0 34,467 63.3
Tumor site
Colon 8,119 64.1 13,577 62.3 21,696 62.6
Rectosigmoid 807 6.4 1,512 6.9 2,319 65.2
Rectum 3,739 29.5 6,713 30.8 10,452 64.2
Total 12,665 100.0 21,802 100.0 34,467 63.3
Dukes’ stage of disease at diagnosis
A 1,915 15.1 3,533 16.2 5,448 64.8
B 3,935 31.1 7,376 33.8 11,311 65.2
C 4,051 32.0 7,638 35.0 11,689 65.3
D 958 7.6 1,379 6.3 2,337 59.0
Not known 1,806 14.3 1,876 8.6 3,682 51.0
Total 12,665 100.0 21,802 100.0 34,467 63.3
NOTE. Based on cancer registry data available for all eligible individuals.
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Table A2.Missing Response Data by Question
Question No. Description No. of Responses Total No. of Respondents
Missing Responses
No. %
1 Treatment 21,328 21,802 474 2.2
3 Disease status 20,550 21,802 1252 5.7
4 Stoma status 19,686 21,802 2116 9.7
5-9 EuroQol-5D (all domains) 20,794 21,802 1008 4.6
12 Bowel control 14,525 15,199 674 4.4
14 Diarrhea 14,121 15,199 1078 7.1
17 Difficulty urinating 19,948 21,802 1854 8.5
18 Urinate more frequently 20,157 21,802 1645 7.5
19 Leak urine 19,956 21,802 1846 8.5
38 Sexual difficulties 20,539 21,802 1263 5.8
40 Body image 20,780 21,802 1022 4.7
72 Long-term conditions 20,631 21,802 1171 5.4
76 Ethnicity 21,212 21,802 590 2.7
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